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« The clinical and economic burden of nonadherence with oral bisphosphonates 
in osteoporotic patients »
INTRODUCTION
Poor compliance and failure to persist with osteoporosis 
medications are common, but the clinical and economic 
consequences have not been well described.
This study aims to estimate the clinical and economic 
burden of nonadherence with oral bisphosphonates in 
osteoporotic patients.
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METHODS
A validated microsimulation model [1] estimated costs and 
outcomes (the number of fractures and the quality-adjusted life-
year (QALY) gained) for three adherence scenarios: no 
treatment, real-world adherence and full adherence over 3 years. 
The real-world adherence scenario employed adherence data 
from a published Belgian study [2]. Adherence was divided into 
persistence and compliance. Real-world persistence assumed 
that 42% of patients go off within the first six months of therapy 
and that 18.1% and 13.9% stop therapy after 1 and 2 years 
respectively [2]. Patients with low compliance (medical 
possession ratio (MPR) less than 80%) were associated with a 
35% increase in hip fracture rate [2] and with a 17% increase in
other fracture rates [3]. The relative risks from clinical trials 
were applicable to the population with high compliance (MPR 
of 80% or greater). The target population, including 29,167 
women, was assumed to be uniformly distributed between 55 
and 85 years of age and to have a bone mineral density T-score 
below –2.5 SD or a prevalent vertebral fracture. The 
incremental cost per QALY gained was estimated comparing 
the three adherence scenarios. We also examined the clinical 
and economic implications of adherence-enhancing 
interventions assuming that adherence failure would be reduced 
by 10%, 20% or 30%. 
CONCLUSIONS
¾More than half of the potential benefits from oral
bisphosphonates in patients with osteoporosis are 
lost due to poor compliance and failure to persist. 
¾ Depending on its cost, interventions that improve 
adherence to therapy have the potential to be an 
attractive use of resources. 
¾ So, therapies that optimize adherence should 
remain cost-effective compared to oral
bisphosphonates even if they cost up to €150 more, 
per year, and may therefore represent a promising 
approach to reduce clinical and economic 
consequences of osteoporosis.
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RESULTS
The estimated number of fractures prevented and 
the lifetime QALY gained in the real-world 
adherence scenario represents only 42.0% and 
41.9% to that obtained under full adherence 
scenario, respectively (Figure 1). Lifetime costs 
under full adherence scenario were lower than in 
the real-world scenario because of money saved 
by preventing fractures (Table 1). The cost per 
QALY gained of real-world adherence versus no 
treatment was estimated at €11,175, and full 
adherence scenario was found to be cost-saving 
compared to real-world adherence. Interventions 
that decrease adherence failure by 10%, 20% and 
30% were associated with an increase in the 
number of fractures prevented of 15%, 28% and 
42%, respectively.
Figure 1: Prediction of the number of 
fracture over a 6-year period within the 










Table 1: Lifetime costs, QALYs and ICER 
between alternative scenarios
Figure 2: The cost-effectiveness of 
adherence-enhancing interventions
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